• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login

    Investing News NetworkYour trusted source for investing success

    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Biotech Market
    Biotech News
    Biotech Stocks
    • Biotech Market
    • Biotech News
    • Biotech Stocks

    BriaCell Approved by FDA for BriaVax Testing

    Bryan Mc Govern
    Mar. 15, 2017 08:39AM PST
    Biotech Investing

    BriaCell Therapeutics (TSX VENTURE:BCT) (OTCQB:BCTXF) has been cleared by the FDA to begin an open-label Phase I/IIa trial of its product BriaVax in patients with advanced breast cancer.

    BriaCell Therapeutics (TSX VENTURE:BCT) (OTCQB:BCTXF) has been cleared by the FDA to begin an open-label Phase I/IIa trial of its product BriaVax in patients with advanced breast cancer.
    As quoted in the press release:

    BriaVax™, the Company’s lead product candidate, is a genetically engineered whole-cell vaccine derived from a human breast tumor cell line.
    “We are excited to further advance clinical development of our novel targeted immunotherapy, BriaVax™, which has previously demonstrated impressive safety and efficacy results in prior clinical evaluation,” stated Dr. Bill Williams, President and CEO of BriaCell Therapeutics. “The upcoming Phase I/IIa clinical trial is designed to determine the optimal dosing regimen for patients, further assess the vaccine’s safety profile, and provide additional efficacy findings including survival rate. The clinical trial will also provide important data to help establish our companion diagnostic, BriaDx™, to determine those patients most likely to respond to BriaVax™ treatment.”
    “We urgently need a new approach to rescue patients with advanced breast cancer as the currently available medications fail in all but a few percent,” commented Dr. Charles Wiseman, inventor of BriaVax™. “Our previously published results in a small number of patients showed that BriaVax™ could induce rapid and widespread tumor regression and the patients had better than expected survival. This study will build on those results.”
    About the Phase I/IIa Clinical Trial Protocol
    The Phase I/IIa clinical trial is an open-label study enrolling up to 24 late-stage breast cancer patients with recurrent and/or metastatic disease. Patients will be administered BriaVax™ every two weeks for the first month of treatment, then monthly up to one year.
    The primary objective of the clinical trial is to evaluate the safety of BriaVax™ in study subjects, and the principal secondary objective is an evaluation of the tumor size reduction. Tumor response will be monitored every three months during the study. The trial will also evaluate progression-free survival (PFS) and overall survival (OS).

    For additional details regarding the clinical trial, please visit: https://www.clinicaltrials.gov/ct2/show/NCT03066947.

    ABOUT BRIACELL
    BriaCell is an immuno-oncology focused biotechnology company developing a more targeted, less toxic approach to cancer management. BriaCell’s mission is to serve late-stage cancer patients with no available treatment options.
    Immunotherapy has come to the forefront of the fight against cancer, harnessing the body’s own immune system in recognizing and selectively destroying the cancer cells while sparing normal ones. Immunotherapy, in addition to generally being more targeted and less toxic than commonly used types of chemotherapy, is also thought to be a strong type of approach aimed at preventing cancer recurrence.
    BriaVax™, the Company’s lead product candidate, is a genetically engineered whole-cell vaccine derived from a human breast tumor cell line. It is believed to activate the immune system to recognize and eliminate cancerous cells by inducing tumor-directed T cell and potentially antibody responses. The Company has already demonstrated encouraging clinical results, and is intent on building upon these results to further advance BriaVax™ through additional FDA-approved clinical trials in order to help cancer patients with limited therapeutic options. The results of two previous Phase I clinical trials (one with the precursor cell line not genetically engineered to produce GM-CSF and one with BriaVax™) have been encouraging in patients with advanced solid tumors. Most notably, one patient with metastatic breast cancer responded to BriaVax™ with substantial reduction in tumor burden including lung and brain metastases.
    For additional information on BriaCell, please visit our website: https://briacell.com/

    Click here to read the full press release.

    clinical trialscancer managementclinical resultsbreast cancer
    The Conversation (0)
    Go Deeper
    AI Powered
    AbbVie Features New Data Across Difficult-to-Treat Solid Tumors and Blood Cancers at ASCO 2025, Highlighting Breadth and Depth of its Oncology Portfolio

    AbbVie Features New Data Across Difficult-to-Treat Solid Tumors and Blood Cancers at ASCO 2025, Highlighting Breadth and Depth of its Oncology Portfolio

    Biotech Outlook: World Edition

    Biotech Outlook: World Edition

    Latest News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Biotech Investing Stocks

    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×